74. 下垂体性PRL分泌亢進症 Prolactin secreting pituitary adenoma Clinical trials / Disease details
臨床試験数 : 19 / 薬物数 : 28 - (DrugBank : 10) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2200056078 | 2022-03-01 | 2022-01-31 | Germinated barley (Maiya) plus bromocriptine in prolactinoma | Germinated barley (Maiya) plus bromocriptine in prolactinoma, a randomized clinical trial | prolactinoma | Group A:Germinated barley (Maiya) plus bromocriptine;Group B:Bromocriptine; | Huashan Hospital | NULL | Pending | 18 | 70 | Both | Group A:30;Group B:30; | China | |
| 2 | NCT04107480 (ClinicalTrials.gov) | June 21, 2019 | 27/8/2019 | PRolaCT - Three Prolactinoma RCTs | PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials | Prolactinoma;Prolactin-Producing Pituitary Tumor | Procedure: Endoscopic trans-sphenoidal adenoma resection;Drug: Dopamine Agonists | Leiden University Medical Center | NULL | Recruiting | 18 Years | N/A | All | 880 | Phase 4 | Netherlands |
| 3 | NCT03717454 (ClinicalTrials.gov) | December 1, 2018 | 14/10/2018 | Dopamine D2 Receptors(D2R) Imaging in Prolactinomas | The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of of Prolactinomas. | Prolactinoma | Other: Surgery;Drug: Drug treatment | Zhebao Wu | Xinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General Hospital | Not yet recruiting | 18 Years | 65 Years | All | 50 | N/A | NULL |
| 4 | NCT03400865 (ClinicalTrials.gov) | October 25, 2018 | 8/1/2018 | Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas | The Effect of Combined Treatment of Cabergoline With Hydroxychloroquine/Chloroquine for Resistant Prolactinomas | Resistance, Disease;Prolactinoma | Drug: HCQ/CQ and CAB combined treatment | Zhebao Wu | Xinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General Hospital | Not yet recruiting | 18 Years | 70 Years | All | 30 | N/A | China |
| 5 | NCT03457389 (ClinicalTrials.gov) | February 22, 2018 | 23/1/2018 | Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma | Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma: A Prospective, Randomized, Open Label, Active-controlled, Clinical Trial | Pituitary Adenoma;Prolactinoma;Pituitary Tumor;Recurrence Tumor | Drug: Cabergoline | Seoul National University Hospital | NULL | Recruiting | 19 Years | N/A | All | 68 | N/A | Korea, Republic of |
| 6 | NCT03038308 (ClinicalTrials.gov) | September 16, 2016 | 30/1/2017 | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability | Hyperprolactinemia;Prolactinoma | Drug: Ropinirole | Columbia University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Active, not recruiting | 18 Years | 70 Years | All | 23 | Phase 1/Phase 2 | United States |
| 7 | NCT03353025 (ClinicalTrials.gov) | January 1, 2016 | 20/2/2017 | Study on Therapy of Non-invasive Prolactinoma | Prospective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive Prolactinoma | Prolactinoma | Procedure: transsphenoidal surgery treatment;Drug: dopamine agonist treatment | First Affiliated Hospital, Sun Yat-Sen University | NULL | Recruiting | 18 Years | 60 Years | All | 394 | N/A | China |
| 8 | ChiCTR-ONC-12002194 | 2012-05-01 | 2012-05-22 | Artery Endothelium Function, Carotid Artery Intima-Media Thickness and Cardiac Mass and Function after Long-Term Control of Hyperprolactimia | Artery Endothelium Function, Carotid Artery Intima-Media Thickness and Cardiac Mass and Function after Long-Term Control of Hyperprolactimia | prolactinoma | patients with prolactinoma:treatment with bromocriptine ; | First affiliated hospital of Sun Yat-sen University | NULL | Completed | 13 | 55 | Both | patients with prolactinoma:40; | NULL | |
| 9 | NCT01344291 (ClinicalTrials.gov) | July 2011 | 18/4/2011 | Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients | Hyperprolactinoma | Drug: Curcumin | Mashhad University of Medical Sciences | NULL | Recruiting | 20 Years | 45 Years | Female | 30 | Phase 1 | Iran, Islamic Republic of | |
| 10 | NCT01088763 (ClinicalTrials.gov) | March 2010 | 16/3/2010 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA | Childhood Atypical Teratoid/Rhabdoid Tumor;Childhood Central Nervous System Choriocarcinoma;Childhood Central Nervous System Germinoma;Childhood Central Nervous System Mixed Germ Cell Tumor;Childhood Central Nervous System Teratoma;Childhood Central Nervous System Yolk Sac Tumor;Childhood Choroid Plexus Tumor;Childhood Craniopharyngioma;Childhood Ependymoblastoma;Childhood Grade I Meningioma;Childhood Grade II Meningioma;Childhood Grade III Meningioma;Childhood Infratentorial Ependymoma;Childhood Medulloepithelioma;Childhood Mixed Glioma;Childhood Oligodendroglioma;Childhood Supratentorial Ependymoma;Gonadotroph Adenoma;Pituitary Basophilic Adenoma;Pituitary Chromophobe Adenoma;Pituitary Eosinophilic Adenoma;Prolactin Secreting Adenoma;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Anaplastic Large Cell Lymphoma;Recurrent Childhood Brain Stem Glioma;Recurrent Childhood Central Nervous System Embryonal Tumor;Recurrent Childhood Cerebellar Astrocytoma;Recurrent Childhood Cerebral Astrocytoma;Recurrent Childhood Ependymoma;Recurrent Childhood Grade III Lymphomatoid Granulomatosis;Recurrent Childhood Large Cell Lymphoma;Recurrent Childhood Lymphoblastic Lymphoma;Recurrent Childhood Medulloblastoma;Recurrent Childhood Pineoblastoma;Recurrent Childhood Small Noncleaved Cell Lymphoma;Recurrent Childhood Spinal Cord Neoplasm;Recurrent Childhood Subependymal Giant Cell Astrocytoma;Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;Recurrent Childhood Visual Pathway and Hypothalamic Glioma;Recurrent Childhood Visual Pathway Glioma;Recurrent Pituitary Tumor;Recurrent/Refractory Childhood Hodgkin Lymphoma;T-cell Childhood Acute Lymphoblastic Leukemia;T-cell Large Granular Lymphocyte Leukemia;TSH Secreting Adenoma;Unspecified Childhood Solid Tumor, Protocol Specific | Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;Other: diagnostic laboratory biomarker analysis;Other: pharmacological study;Drug: dexamethasone | National Cancer Institute (NCI) | NULL | Terminated | 1 Year | 21 Years | Both | 129 | Phase 1 | United States;Canada |
| 11 | NCT01620138 (ClinicalTrials.gov) | March 2010 | 18/9/2011 | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist | Non-functioning Pituitary Adenomas;Prolactinomas | Drug: Pasireotide;Drug: cabergoline | Universidade Federal do Rio de Janeiro | NULL | Completed | 18 Years | N/A | All | 21 | Phase 2/Phase 3 | Brazil |
| 12 | EUCTR2008-007348-32-IT (EUCTR) | 07/09/2009 | 07/08/2009 | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - ND | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - ND | 1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)3. Ectopic ACTH-secreting (EAS) tumors4. Nelsons syndrome MedDRA version: 9.1;Level: LLT;Classification code 10051747 | Product Name: PASIREOTIDE Product Code: SOM230 INN or Proposed INN: PASIREOTIDE Product Name: PASIREOTIDE Product Code: SOM230 INN or Proposed INN: PASIREOTIDE Product Name: PASIREOTIDE Product Code: SOM230 INN or Proposed INN: PASIREOTIDE | NOVARTIS FARMA | NULL | Not Recruiting | Female: yes Male: yes | 70 | France;Spain;Germany;Italy | |||
| 13 | EUCTR2008-007348-32-DE (EUCTR) | 12/08/2009 | 30/06/2009 | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NA | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NA | The following tumors are included:1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)3. Ectopic ACTH-secreting (EAS) tumors4. Nelson's syndrome MedDRA version: 14.1;Level: LLT;Classification code 10062476;Term: Neuroendocrine tumor;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: Pasireotide Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: Pasireotide Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: Pasireotide | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | United States;Spain;Russian Federation;Colombia;Italy;France;Mexico;Canada;Argentina;Brazil;Australia;South Africa;Germany | ||
| 14 | EUCTR2009-010918-30-IE (EUCTR) | 11/08/2009 | 11/03/2009 | Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism. | Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism. | 20 patients with hypopituitarism including growth hormone deficiency will be evaluated both on growth hormone replacement and when they have been off it for a 2 month period. They will have been prescribed growth hormone replacement in the form of Genotropin/Genotropin Miniquick/Norditropin prior to inclusion in this study as part of their routine clinical care. MedDRA version: 9.1;Level: LLT;Classification code 10021067;Term: Hypopituitarism MedDRA version: 9.1;Classification code 10033662;Term: Panhypopituitarism MedDRA version: 9.1;Classification code 10056438;Term: Growth hormone deficiency MedDRA version: 9.1;Classification code 10011318;Term: Craniopharyngioma MedDRA version: 9.1;Classification code 10036832;Term: Prolactinoma MedDRA version: 9.1;Classification code 10011651;Term: Cushing's disease MedDRA version: 9.1;Classification code 10035104;Term: Pituitary tumour MedDRA version: 9.1;Classification code 10061538;Term: Pituitary tumour benign | Trade Name: Genotropin 5.3mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin 12mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin Miniquick 0.2mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin Miniquick 0.4mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin Miniquick 0.6mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin Miniquick 0.8mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin Miniquick 1.0mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin Miniquick 1.2mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin Miniqu | Amar Agha, Beaumont Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Ireland | |||
| 15 | NCT00939523 (ClinicalTrials.gov) | July 2009 | 14/7/2009 | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | Pituitary Adenomas;Prolactinomas | Drug: Lapatinib | Cedars-Sinai Medical Center | NULL | Completed | 18 Years | N/A | All | 9 | Phase 2 | United States |
| 16 | EUCTR2008-007348-32-FR (EUCTR) | 06/05/2009 | 05/06/2009 | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NA | An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NA | The following tumors are included:1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)3. Ectopic ACTH-secreting (EAS) tumors4. Nelson’s syndrome MedDRA version: 9.1;Level: LLT;Classification code 10062476;Term: Neuroendocrine tumor | Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: Pasireotide Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: Pasireotide Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: Pasireotide | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | France;Spain;Germany;Italy | ||
| 17 | EUCTR2006-007036-95-DE (EUCTR) | 02/07/2008 | 23/01/2009 | Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study | Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study | Prolactinoma MedDRA version: 9.1;Level: LLT;Classification code 10036832;Term: Prolactinoma | Product Code: SOM230 INN or Proposed INN: Pasireotide Product Code: SOM230 INN or Proposed INN: Pasireotide | Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für Endokrinologie | NULL | Not Recruiting | Female: yes Male: yes | Germany | ||||
| 18 | NCT00460616 (ClinicalTrials.gov) | January 2007 | 13/4/2007 | Cardiac Valve Complications in Prolactinomas Treated With Cabergoline | Observational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With Cabergoline | Prolactinomas | Drug: Cabergoline | Federico II University | NULL | Completed | 18 Years | 65 Years | Both | 50 | Italy | |
| 19 | NCT00697814 (ClinicalTrials.gov) | June 2004 | 12/6/2008 | Clomiphene in Males With Prolactinomas and Persistent Hypogonadism | Recovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent Hypogonadism | Hypogonadotropic Hypogonadism;Prolactinoma | Drug: Clomiphene citrate | Federal University of São Paulo | NULL | Completed | 18 Years | 70 Years | Male | 15 | Phase 2 | Brazil |